Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs

Basit Öğe Kaydı
dc.authoridParlakpinar, Hakan/0000-0001-9497-3468
dc.authoridGunata, Mehmet/0000-0001-6905-4259
dc.authoridParlakpınar, Hakan/0000-0001-9497-3468
dc.authorwosidParlakpinar, Hakan/V-6637-2019
dc.authorwosidGunata, Mehmet/AAW-2738-2021
dc.authorwosidParlakpınar, Hakan/T-6517-2018
dc.contributor.authorParlakpinar, Hakan
dc.contributor.authorGunata, Mehmet
dc.date.accessioned2024-08-04T20:50:36Z
dc.date.available2024-08-04T20:50:36Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractImmunosuppressive drugs used in the transplantation period are generally defined as induction and maintenance therapy. The use of immunosuppressants, which are particularly useful and have fewer side effects, decreased both mortality and morbidity. Many drugs such as steroids, calcineurin inhibitors (cyclosporine-A, tacrolimus), antimetabolites (mycophenolate mofetil, azathioprine), and mTOR inhibitors (sirolimus, everolimus) are used as immunosuppressive agents. Although immunosuppressant drugs cause many side effects such as hypertension, infection, and hyperlipidemia, they are the agents that should be used to prevent organ rejection. This shows the importance of individualized drug use. The optimal immunosuppressive therapy post-transplant is not established. Therefore, discovering less toxic but more potent new agents is of great importance, and new experimental and clinical studies are needed in this regard. Our review discussed the mechanism of immunosuppressants, new agents' discovery, and current therapeutic protocols in the transplantation.en_US
dc.identifier.doi10.1080/08923973.2021.1966033
dc.identifier.endpage665en_US
dc.identifier.issn0892-3973
dc.identifier.issn1532-2513
dc.identifier.issue6en_US
dc.identifier.pmid34415233en_US
dc.identifier.scopus2-s2.0-85113778160en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage651en_US
dc.identifier.urihttps://doi.org/10.1080/08923973.2021.1966033
dc.identifier.urihttps://hdl.handle.net/11616/100170
dc.identifier.volume43en_US
dc.identifier.wosWOS:000686819900001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofImmunopharmacology and Immunotoxicologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmunosuppressanten_US
dc.subjecttransplant pharmacisten_US
dc.subjectsignaling pathwaysen_US
dc.subjectrejectionen_US
dc.subjectmolecular biologyen_US
dc.titleTransplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugsen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu